Home / Generics / News / Teva launches generic acamprosate in US

Teva launches generic acamprosate in US Posted 08/04/2016

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 22 March 2016 that it had launched a generic version of alcohol dependence treatment Campral (acamprosate).

Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcohol withdrawal.

The originator product Campral is manufactured in the US by Forest Laboratories, while Merck KGaA markets it outside the US. Campral was only approved by the US Food and Drug Administration (FDA) on 29 July 2004, however, it has been legal in Europe since 1989.

Teva has launched its generic as 333 mg acamprosate calcium delayed-release tablets, which is the equivalent of 300 mg of acamprosate. The company points out that treatment with acamprosate calcium delayed-release tablets helps maintain abstinence from alcohol only when used as part of a treatment programme that includes counselling and support.

Acamprosate calcium delayed-release tablets had annual sales of approximately US$14 million in the US, according to IMS data as of December 2015.

Generics makers Barr Laboratories, Glenmark Generics and Mylan also have acamprosate generics approved in the US.

Teva claims to have the largest portfolio of FDA approved generics on the market and states that it has over 375 generics available in the US.

Related article

Tentative FDA approval for chemotherapy generic

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro PharmaCommunications International. All Rights Reserved.

Source: US FDA, Teva

Comments (0)